NovAccess Global Inc. (XSNX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.86 Million USD | 64.52% |
| 2022 | 4.77 Million USD | 15.52% |
| 2021 | 4.13 Million USD | 15.86% |
| 2020 | 3.56 Million USD | 45.64% |
| 2019 | 2.45 Million USD | -48.85% |
| 2018 | 4.79 Million USD | 338.61% |
| 2017 | 1.09 Million USD | 20.54% |
| 2016 | 906.35 Thousand USD | -6.96% |
| 2015 | 974.11 Thousand USD | 0.19% |
| 2014 | 972.23 Thousand USD | 2.98% |
| 2013 | 944.13 Thousand USD | 25.61% |
| 2012 | 751.65 Thousand USD | 2.99% |
| 2011 | 729.82 Thousand USD | -22.76% |
| 2010 | 944.83 Thousand USD | 5.82% |
| 2009 | 892.83 Thousand USD | 79.68% |
| 2008 | 496.91 Thousand USD | 58.92% |
| 2007 | 312.68 Thousand USD | -46.88% |
| 2006 | 588.69 Thousand USD | -39.57% |
| 2005 | 974.23 Thousand USD | 913.11% |
| 2004 | 96.16 Thousand USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 414.2 Thousand USD | 12.89% |
| 2001 | 366.9 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 6.44 Million USD | -17.99% |
| 2024 Q3 | 7.69 Million USD | 10.94% |
| 2024 Q2 | 6.93 Million USD | 7.65% |
| 2023 Q3 | 6.4 Million USD | 9.95% |
| 2023 Q2 | 5.83 Million USD | -17.71% |
| 2023 FY | 7.86 Million USD | 64.52% |
| 2023 Q4 | 7.86 Million USD | 22.63% |
| 2023 Q1 | 7.08 Million USD | 48.28% |
| 2022 Q2 | 4.68 Million USD | 16.25% |
| 2022 Q3 | 4.79 Million USD | 2.37% |
| 2022 Q4 | 4.77 Million USD | -0.3% |
| 2022 FY | 4.77 Million USD | 15.52% |
| 2022 Q1 | 4.02 Million USD | -2.63% |
| 2021 Q1 | 2.3 Million USD | -35.3% |
| 2021 Q2 | 2.72 Million USD | 18.15% |
| 2021 Q3 | 4.48 Million USD | 64.36% |
| 2021 Q4 | 4.13 Million USD | -7.78% |
| 2021 FY | 4.13 Million USD | 15.86% |
| 2020 Q1 | 2.8 Million USD | 14.58% |
| 2020 Q4 | 3.56 Million USD | 199.3% |
| 2020 Q2 | 2.5 Million USD | -10.71% |
| 2020 Q3 | 1.19 Million USD | -52.44% |
| 2020 FY | 3.56 Million USD | 45.64% |
| 2019 Q1 | 3.42 Million USD | -28.61% |
| 2019 Q2 | 2.94 Million USD | -14.03% |
| 2019 Q4 | 2.45 Million USD | -28.53% |
| 2019 FY | 2.45 Million USD | -48.85% |
| 2019 Q3 | 3.42 Million USD | 16.62% |
| 2018 Q1 | 954.4 Thousand USD | -12.64% |
| 2018 Q4 | 4.79 Million USD | -37.78% |
| 2018 Q3 | 7.7 Million USD | 488.42% |
| 2018 Q2 | 1.3 Million USD | 37.13% |
| 2018 FY | 4.79 Million USD | 338.61% |
| 2017 Q3 | 876.65 Thousand USD | -12.61% |
| 2017 FY | 1.09 Million USD | 20.54% |
| 2017 Q4 | 1.09 Million USD | 24.62% |
| 2017 Q2 | 1 Million USD | 0.93% |
| 2017 Q1 | 993.9 Thousand USD | 9.66% |
| 2016 Q4 | 906.35 Thousand USD | 9.26% |
| 2016 Q1 | 1.01 Million USD | 4.46% |
| 2016 Q2 | 797.69 Thousand USD | -21.61% |
| 2016 Q3 | 829.5 Thousand USD | 3.99% |
| 2016 FY | 906.35 Thousand USD | -6.96% |
| 2015 FY | 974.11 Thousand USD | 0.19% |
| 2015 Q4 | 974.11 Thousand USD | 51.0% |
| 2015 Q3 | 645.13 Thousand USD | -18.37% |
| 2015 Q2 | 790.3 Thousand USD | -22.03% |
| 2015 Q1 | 1.01 Million USD | 4.25% |
| 2014 Q4 | 972.23 Thousand USD | -0.69% |
| 2014 FY | 972.23 Thousand USD | 2.98% |
| 2014 Q1 | 1.02 Million USD | 8.22% |
| 2014 Q3 | 978.99 Thousand USD | -9.74% |
| 2014 Q2 | 1.08 Million USD | 6.16% |
| 2013 Q1 | 974.67 Thousand USD | 29.67% |
| 2013 Q4 | 944.13 Thousand USD | -3.92% |
| 2013 FY | 944.13 Thousand USD | 25.61% |
| 2013 Q3 | 982.66 Thousand USD | -2.17% |
| 2013 Q2 | 1 Million USD | 3.05% |
| 2012 Q2 | 788.79 Thousand USD | 23.61% |
| 2012 Q4 | 751.65 Thousand USD | -2.97% |
| 2012 FY | 751.65 Thousand USD | 2.99% |
| 2012 Q3 | 774.65 Thousand USD | -1.79% |
| 2012 Q1 | 638.13 Thousand USD | -12.56% |
| 2011 Q1 | 940.47 Thousand USD | -0.46% |
| 2011 Q2 | 714.94 Thousand USD | -23.98% |
| 2011 Q3 | 701.43 Thousand USD | -1.89% |
| 2011 Q4 | 729.82 Thousand USD | 4.05% |
| 2011 FY | 729.82 Thousand USD | -22.76% |
| 2010 Q3 | 985.55 Thousand USD | -4.76% |
| 2010 FY | 944.83 Thousand USD | 5.82% |
| 2010 Q2 | 1.03 Million USD | 1.13% |
| 2010 Q4 | 944.83 Thousand USD | -4.13% |
| 2010 Q1 | 1.02 Million USD | 14.61% |
| 2009 Q1 | 3.75 Million USD | 655.72% |
| 2009 Q2 | 1.62 Million USD | -56.72% |
| 2009 FY | 892.83 Thousand USD | 79.68% |
| 2009 Q4 | 892.83 Thousand USD | -42.65% |
| 2009 Q3 | 1.55 Million USD | -4.2% |
| 2008 Q1 | 293.97 Thousand USD | -5.98% |
| 2008 FY | 496.91 Thousand USD | 58.92% |
| 2008 Q4 | 496.91 Thousand USD | 234.66% |
| 2008 Q3 | 148.48 Thousand USD | -51.14% |
| 2008 Q2 | 303.86 Thousand USD | 3.36% |
| 2007 Q2 | 501.49 Thousand USD | -10.83% |
| 2007 Q1 | 562.42 Thousand USD | -4.46% |
| 2007 Q4 | 312.68 Thousand USD | -41.69% |
| 2007 FY | 312.68 Thousand USD | -46.88% |
| 2007 Q3 | 536.26 Thousand USD | 6.93% |
| 2006 Q4 | 588.69 Thousand USD | -81.37% |
| 2006 Q2 | 6.35 Million USD | 115.97% |
| 2006 Q3 | 3.16 Million USD | -50.26% |
| 2006 Q1 | 2.94 Million USD | 202.01% |
| 2006 FY | 588.69 Thousand USD | -39.57% |
| 2005 Q4 | 974.23 Thousand USD | 175.76% |
| 2005 Q1 | 81.96 Thousand USD | -14.77% |
| 2005 Q2 | 236.8 Thousand USD | 188.91% |
| 2005 FY | 974.23 Thousand USD | 913.11% |
| 2005 Q3 | 353.29 Thousand USD | 49.19% |
| 2004 FY | 96.16 Thousand USD | 0.0% |
| 2004 Q2 | 91.37 Thousand USD | 122.34% |
| 2004 Q3 | 142.8 Thousand USD | 56.29% |
| 2004 Q4 | 96.16 Thousand USD | -32.66% |
| 2004 Q1 | 41.09 Thousand USD | 0.0% |
| 2003 Q2 | 415.46 Thousand USD | 0.0% |
| 2003 Q1 | 415.46 Thousand USD | 0.3% |
| 2003 FY | - USD | -100.0% |
| 2003 Q3 | 428.64 Thousand USD | 3.17% |
| 2003 Q4 | - USD | -100.0% |
| 2002 Q2 | 274.15 Thousand USD | 6.65% |
| 2002 Q1 | 257.06 Thousand USD | -29.94% |
| 2002 Q3 | 274.73 Thousand USD | 0.21% |
| 2002 Q4 | 414.2 Thousand USD | 50.77% |
| 2002 FY | 414.2 Thousand USD | 12.89% |
| 2001 FY | 366.9 Thousand USD | 0.0% |
| 2001 Q2 | 688.74 Thousand USD | 0.92% |
| 2001 Q3 | 698.61 Thousand USD | 1.43% |
| 2001 Q4 | 366.9 Thousand USD | -47.48% |
| 2001 Q1 | 682.48 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -28554.292% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 16.958% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 89.153% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -871.908% |
| Rebus Holdings, Inc. | 5.24 Million USD | -49.957% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 86.68% |
| Qrons Inc. | 1.48 Million USD | -428.022% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -541.058% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 89.508% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -17487.104% |
| Skye Bioscience, Inc. | 14.07 Million USD | 44.14% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 85.253% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 17.964% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1764.642% |
| SQZ Biotechnologies Company | 50.03 Million USD | 84.291% |
| Intellipharmaceutics International Inc. | 12 Million USD | 34.542% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -104.099% |
| Mesoblast Limited | 188.44 Million USD | 95.829% |
| Marizyme, Inc. | 26.67 Million USD | 70.532% |
| Genus plc | 485 Million USD | 98.379% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -34.541% |
| Pharming Group N.V. | 244.07 Million USD | 96.779% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -291.056% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -212.389% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -106.861% |
| ContraFect Corporation | 32.53 Million USD | 75.836% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -296.745% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -105.367% |
| IMV Inc. | 37.93 Million USD | 79.277% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 33.26% |
| MultiCell Technologies, Inc. | 1617.67 USD | -485829.269% |
| ONE Bio Corp. | 27.49 Million USD | 71.411% |
| Accustem Sciences Inc. | 1.07 Million USD | -628.359% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 89.846% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -271.654% |
| Q BioMed Inc. | 8.13 Million USD | 3.347% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 90.522% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -52.753% |
| Biomind Labs Inc. | 1.49 Million USD | -424.534% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 93.379% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 13.066% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 57.287% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -448.221% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -5432.026% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -3808.556% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -36.808% |
| GB Sciences, Inc. | 5.41 Million USD | -45.097% |
| Alpha Cognition Inc. | 7.16 Million USD | -9.714% |
| HST Global, Inc. | 593.59 Thousand USD | -1224.263% |
| CSL Limited | 18.62 Billion USD | 99.958% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -524.267% |
| Halberd Corporation | 728.71 Thousand USD | -978.706% |
| Enzolytics Inc. | 365.26 Million USD | 97.848% |
| Agentix Corp. | 2.51 Million USD | -213.107% |
| Resverlogix Corp. | 67.39 Million USD | 88.337% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -837.216% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.233% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -358.619% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 68.234% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 33.961% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -114.471% |
| AVAX Technologies, Inc. | 3.99 Million USD | -96.826% |
| Zenith Capital Corp. | 27.56 Thousand USD | -28412.938% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.407% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -3193.778% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -110.5% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1054.574% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -189.888% |
| Kadimastem Ltd | 3.5 Million USD | -124.28% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -11644.882% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 84.361% |
| BioStem Technologies, Inc. | 15.9 Million USD | 50.576% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1591.575% |
| LadRx Corporation | 2.2 Million USD | -257.22% |
| Cell Source, Inc. | 15.8 Million USD | 50.27% |
| Regen BioPharma, Inc. | 5.45 Million USD | -44.032% |
| Regen BioPharma, Inc. | 5.45 Million USD | -44.032% |
| Affymax, Inc. | 8.87 Million USD | 11.388% |
| Itoco Inc. | 1.65 Million USD | -375.5% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -283.158% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -29.951% |
| Mobile Lads Corp. | 1.31 Million USD | -498.458% |
| CytoDyn Inc. | 127.89 Million USD | 93.854% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -18706.029% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -401.842% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 28.832% |
| SYBLEU INC | 681.41 Thousand USD | -1053.593% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -28.824% |
| International Stem Cell Corporation | 5.27 Million USD | -48.962% |
| Bioxytran, Inc. | 3.24 Million USD | -141.906% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1156.091% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -70.252% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 80.826% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 64.695% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -288.11% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -43.496% |
| Neutra Corp. | 973.52 Thousand USD | -707.447% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 72.908% |
| PureTech Health plc | 125.58 Million USD | 93.741% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -109.222% |
| IXICO plc | 1.9 Million USD | -313.659% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 61.709% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 92.392% |
| CSL Limited | 18.62 Billion USD | 99.958% |
| Cellectis S.A. | 249.36 Million USD | 96.848% |